Department of Nephrology, University of Medicine and Pharmacy Iuliu Hatieganu Cluj Napoca, 8 Victor Babes street, 400012, Cluj Napoca, Romania.
Int Urol Nephrol. 2012 Dec;44(6):1771-7. doi: 10.1007/s11255-011-0118-4. Epub 2012 Jan 6.
The 276G>T polymorphism of the adiponectin (ADIPOQ) gene has been correlated with plasma adiponectin, type 2 diabetes (T2D) and its complications. Studies of the role of 276G>T polymorphism in the prevalence of T2D kidney disease are few and contradictory; ethnic differences might play a role. We aimed to assess the relationship of this polymorphism with albuminuria in a cohort of Caucasian T2D patients.
Consecutive T2D outclinic patients were screened and included upon informed consent; exclusion criteria were glomerular filtration rate (GFR)<30 ml/min, acute intercurrent illness and urinary tract infection. History, standard laboratory evaluation, total plasma adiponectin and genotyping for the 276 ADIPOQ locus were obtained.
One hundred and three T2D patients were included. Forty-three (41.7%) of them had GG genotype, 50 (48.5%) had GT and 10 (9.7%) had TT genotype. Plasma adiponectin was significantly higher in TT-allele carriers (19.03±3.46 μg/ml) than in GT (10.14±1.78 μg/ml) and GG carriers (8.71±1.60 μg/ml), P=0.003. Adiponectin was higher in albuminuric (13.97±2.07 μg/ml) than in normoalbuminuric patients (6.91±0.88 μg/ml), P=0.004. The prevalence of T allele was higher in normoalbuminuric patients [36 (69.2%) GT+TT carriers] than in albuminuric ones [24 (47.1%)], P=0.02. Logistic regression identified the following as predictors of albuminuria: GG genotype: P=0.003 (OR 4.2; CI 1.61-10.96); low GFR: P=0.003 (OR 0.97; CI 0.95-0.99); and high plasma adiponectin: P=0.012 (OR 1.07; CI 1.01-1.14).
Our data suggest that 276G>T polymorphism of the ADIPOQ gene is associated with plasma adiponectin levels. By influencing adiponectinemia, 276G>T polymorphism might predict the presence of albuminuria in Caucasian T2D patients.
脂联素(ADIPOQ)基因的 276G>T 多态性与血浆脂联素、2 型糖尿病(T2D)及其并发症有关。关于 276G>T 多态性与 T2D 肾病患病率之间关系的研究很少且存在矛盾;不同种族可能起作用。我们旨在评估该多态性与高加索 T2D 患者蛋白尿之间的关系。
连续筛查 T2D 门诊患者并在获得知情同意后纳入;排除标准为肾小球滤过率(GFR)<30ml/min、急性并发疾病和尿路感染。获取病史、标准实验室评估、总血浆脂联素和 276 个 ADIPOQ 基因座的基因分型。
103 例 T2D 患者入选。其中 43 例(41.7%)为 GG 基因型,50 例(48.5%)为 GT 基因型,10 例(9.7%)为 TT 基因型。TT 等位基因携带者的血浆脂联素(19.03±3.46μg/ml)明显高于 GT(10.14±1.78μg/ml)和 GG 携带者(8.71±1.60μg/ml),P=0.003。白蛋白尿患者的脂联素(13.97±2.07μg/ml)高于非白蛋白尿患者(6.91±0.88μg/ml),P=0.004。非白蛋白尿患者 GT+TT 携带者(36(69.2%))的 T 等位基因频率高于白蛋白尿患者(24(47.1%)),P=0.02。Logistic 回归分析确定以下因素为白蛋白尿的预测因素:GG 基因型:P=0.003(OR 4.2;95%CI 1.61-10.96);低肾小球滤过率:P=0.003(OR 0.97;95%CI 0.95-0.99);和高血浆脂联素:P=0.012(OR 1.07;95%CI 1.01-1.14)。
我们的数据表明,ADIPOQ 基因的 276G>T 多态性与血浆脂联素水平有关。通过影响脂联素血症,276G>T 多态性可能预测高加索 T2D 患者白蛋白尿的存在。